Condition: Stereotypical Prolonged Seizures · Sponsor: UCB Biopharma SRL
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
This description comes directly from the study's public registry record.
UCB Cares · 1-844-599-2273 (USA) · UCBCares@ucb.com
UCB Cares · 0018445992273 · UCBCares@ucb.com
Always discuss trial participation with your own doctor first.
| Ep0162 50506 | Phoenix, Arizona, United States | Recruiting |
| Ep0162 50720 | Scottsdale, Arizona, United States | Recruiting |
| Ep0162 50494 | Little Rock, Arkansas, United States | Completed |
| Ep0162 50118 | Downey, California, United States | Recruiting |
| Ep0162 50416 | La Jolla, California, United States | Recruiting |
| Ep0162 50702 | Long Beach, California, United States | Recruiting |
| Ep0162 50505 | Los Angeles, California, United States | Withdrawn |
| Ep0162 50492 | Orange, California, United States | Completed |
| Ep0162 50722 | Poway, California, United States | Recruiting |
| Ep0162 50716 | Sacramento, California, United States | Recruiting |
| Ep0162 50367 | New Haven, Connecticut, United States | Completed |
| Ep0162 50088 | Washington D.C., District of Columbia, United States | Recruiting |
+ 171 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05077904